Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced Non-Small Cell Lung Cancer Patients Treated with Carboplatin-Gemcitabine Regimen

  • Published : 2016.09.01

Abstract

Background: Platinum-based regimens are effective treatments for advanced non-small cell lung cancer (NSCLC), but the five-year survival rate is still less than 20%. One possible factor appears to be resistance involving polymorphisms in the CTR1 gene which plays an importance role in accumulation of platinum in the cytoplasm. Purpose: To establish both prevalence of CTR1 polymorphism and its impact on treatment related toxicity in Thai advanced NSCLC patients. Materials and Methods: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. These participants were planning to be treated with platinum-based chemotherapy for at least two cycles. Results: Allele frequency of CTR1 polymorphism $G{\rightarrow}T$ was found to be 25%. The results showed that genetic polymorphism at CTR1 rs12686377 was associated with emesis side effects (P = 0.020) and neuropathic symptoms (P = 0.010). In addition, hematologic side effects in terms of anemia also tended to be related to this polymorphism. Conclusions: This is the first study suggesting that polymorphism at CTR1 rs12686377 may be associated with toxicity from platinum-based regimens. Therefore, it could be a factor to aid in treatment decision-making.

Acknowledgement

Supported by : Chulalongkorn University

References

  1. Amable L (2016). Cisplatin resistance and opportunities for precision medicine. Pharmacol Res, 106, 27-36. https://doi.org/10.1016/j.phrs.2016.01.001
  2. Kim ES, Tang X, Peterson DR, et al (2014). Copper transporter CTR1 expression and tissue platinum concentration in nonsmall cell lung cancer. Lung Cancer, 85, 88-93. https://doi.org/10.1016/j.lungcan.2014.04.005
  3. Kommuguri UN, Bodiga S, Sankuru S, et al (2012). Copper deprivation modulates CTR1 and CUP1 expression and enhances cisplatin cytotoxicity in Saccharomyces cerevisiae. J Trace Elem Med Biol, 26, 13-9. https://doi.org/10.1016/j.jtemb.2011.12.001
  4. Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33, 9-23. https://doi.org/10.1016/j.ctrv.2006.09.006
  5. Rinaldi M, Cauchi C, Gridelli C (2006). First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol, 17, 64-7. https://doi.org/10.1093/annonc/mdj953
  6. Rose MC, Kostyanovskaya E, Huang RS (2014). Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genomics Proteomics Bioinformatics, 12, 198-209. https://doi.org/10.1016/j.gpb.2014.10.003
  7. Safaei R, Howell SB (2005). Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol, 53, 13-23. https://doi.org/10.1016/j.critrevonc.2004.09.007
  8. Xu X, Duan L, Zhou B, et al (2012a). Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol, 39, 786-92. https://doi.org/10.1111/j.1440-1681.2012.05741.x
  9. Xu X, Ren H, Zhou B, et al (2012b). Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 77, 438-42. https://doi.org/10.1016/j.lungcan.2012.03.023